Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
Status:
Recruiting
Trial end date:
2022-02-16
Target enrollment:
Participant gender:
Summary
This study will be available to any participant who has received or is currently receiving
belantamab mafodotin treatment through either a clinical trial, an access program, or a
physician prescription. Participants do not need to be on active treatment. The purpose of
this study is to gain a more complete understanding of the pathophysiology of the corneal
events seen in some participants with relapsed/refractory multiple myeloma (RRMM) treated
with belantamab mafodotin. A superficial corneal epithelial tissue specimen will be obtained
by performing impression cytology (IC) or superficial keratectomy (SK) procedure in
participants treated with belantamab mafodotin. The procedure will only be performed in one
eye, most affected by the corneal epithelial changes. This specimen will undergo pathologic
examination and composition analysis. Study duration will be approximately 4 months.
Approximately 25 participants will be enrolled in the study.